Syra Health To Discuss Fourth Quarter and Full Year 2024 Financial Results

Conference call will be held on Tuesday, March 11 at 9:00 a.m. ET

CARMEL, Ind., March 4, 2025 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA), ("Syra Health" or the "Company"), a healthcare technology company dedicated to powering better health through innovative technology products and services, announced today that it will report financial results for its fourth quarter and full year 2024 ended December 31, 2024, on Tuesday, March 11, 2025, before the market opens. The company will host a conference call that same day, March 11, 2025, at 9:00 a.m. ET, to discuss the results.

Interested parties can access the conference call via webcast, available in the investors section of the company's website at https://ir.syrahealth.com/presentations/q4-and-full-year-2024-earnings-call.

Investors who would like to submit a question to be addressed on the call should email corbin@haydenir.com.

A webcast replay will be available in the investors section of the company's website at https://ir.syrahealth.com/presentations/q4-and-full-year-2024-earnings-call.

About Syra Health

Syra Health is a healthcare technology company powering better health in critical areas such as behavioral and mental health, population health, and the healthcare workforce. The company's leading-edge technology products and innovative services focus on prevention, access, and affordability. With a commitment to improving health, Syra Health is advancing healthcare solutions nationwide and around the world. For more information, please visit www.syrahealth.com.

Contacts

For Investor Inquiries:
Corbin Woodhull
Managing Director, Global Advisory
Hayden IR
602-476-1821
corbin@haydenir.com

For Media Inquiries:
Christine Drury
Director of Corporate Communications
Syra Health
463-345-5180
christined@syrahealth.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/syra-health-to-discuss-fourth-quarter-and-full-year-2024-financial-results-302390799.html

SOURCE Syra Health